(Q37815612)

23 August 2017

1 reference

title

Update on capecitabine alone and in combination regimens in colorectal cancer patients (English)

1 reference

23 August 2017

1 reference

1 reference

1 reference

A Azzariti

8

0 references

Gianmauro Numico

G Numico

9

0 references

Stefania Tommasi

S Tommasi

7

0 references

Evaristo Maiello

E Maiello

2

0 references

Daniele Santini

D Santini

5

0 references

author name string

N Silvestris

1

1 reference

23 August 2017

F De Vita

3

1 reference

23 August 2017

S Cinieri

4

1 reference

23 August 2017

A Russo

6

1 reference

23 August 2017

S Pisconti

10

1 reference

23 August 2017

D Petriella

11

1 reference

23 August 2017

V Lorusso

12

1 reference

23 August 2017

A Millaku

13

1 reference

23 August 2017

G Colucci

14

1 reference

23 August 2017

publication date

1 November 2010

1 reference

23 August 2017

published in

Cancer Treatment Reviews

1 reference

23 August 2017

volume

36 Suppl 3

1 reference

23 August 2017

page(s)

S46-55

1 reference

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

The role of capecitabine in the management of tumors of the digestive system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Evolution of capecitabine dosing in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

The use of capecitabine in the combined-modality therapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970020-7

7 January 2021

10.1016/S0305-7372(10)70020-7

Identifiers

DOI

1 reference

23 August 2017

1 reference